Is HIMS Stock Still Undervalued After Settled Lawsuit?

Is Hims & Hers Health ($HIMS) is moving. With the Novo Nordisk lawsuit settled and a new partnership to distribute Wegovy and Ozempic, Barclays thinks this stock is undervalued and they just raised their price target to $29.
Profile Image
Updated Apr 08, 2026   |   12:18 PM EDT
Share
·
Add us onAdd us on Google
$HIMS could be the best comeback story so far this year... Let me know what you think in the comments ⬇️
Follow on Google News
Read about our editorial guidelines and ethics policy